A Collaborative Analysis of Stereotactic Lung Radiotherapy Outcomes for Early-Stage Non–Small-Cell Lung Cancer Using Daily Online Cone-Beam Computed Tomography.

Slides:

Advertisements

Similar presentations

Size matters: A comparison of T1 and T2 peripheral non–small-cell lung cancers treated with stereotactic body radiation therapy (SBRT) Neal E. Dunlap,

Advertisements

Brandon Stone, MD, Victor S. Mangona, MD, Matthew D

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab Tomoko Funazo,

One in every 14 patients with early-stage lung cancer is not being treated! Benny Weksler, MD, MBA The Journal of Thoracic and Cardiovascular Surgery

It is not just about surgery versus stereotactic ablative radiotherapy, it is about curing as many patients with lung cancer as possible Alessandro Brunelli,

Disparities in Treatment of Patients with Inoperable Stage I Non–Small Cell Lung Cancer: A Population-Based Analysis Matthew Koshy, MD, Renuka Malik,

Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database Alex.

Brandon Stone, MD, Victor S. Mangona, MD, Matthew D

Required target margins for image-guided lung SBRT: Assessment of target position intrafraction and correction residuals Chirag Shah, MD, Larry L. Kestin,

Is There a Lower Limit of Pretreatment Pulmonary Function for Safe and Effective Stereotactic Body Radiotherapy for Early-Stage Non-small Cell Lung Cancer?

Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database Alex.

Nivolumab Enhances the Inflammation of the Irradiation Field in Advanced Non–Small Cell Lung Cancer Hiromi Furuta, MD, PhD, Tatsuya Yoshida, MD, PhD,

Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive-Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Study 39901 Stephen L. Graziano,

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

Long-Term Outcomes of Salvage Stereotactic Ablative Radiotherapy for Isolated Lung Recurrence of Non–Small Cell Lung Cancer: A Phase II Clinical Trial

Tumor Regression and Positional Changes in Non-small Cell Lung Cancer During Radical Radiotherapy Gerald Lim, MD, Andrea Bezjak, MD, CM, MSc, Jane Higgins,

Cornelis J. A. Haasbeek, MD, PhD, Frank J. Lagerwaard, MD, PhD, Ben J

Predicting Radiation Esophagitis Using 18F-FDG PET During Chemoradiotherapy for Locally Advanced Non–Small Cell Lung Cancer Qurrat Mehmood, MBChB., Alexander.

The Presence of Mutations in Epidermal Growth Factor Receptor Gene Is Not a Prognostic Factor for Long-Term Outcome after Surgical Resection of Non–Small-Cell.

IA05.01 Lung Cancer Cases Journal of Thoracic Oncology

Treatment and Prognosis of Isolated Local Relapse after Stereotactic Body Radiotherapy for Clinical Stage I Non-Small-Cell Lung Cancer Masatsugu Hamaji,

Lymph Node Ratio May Predict the Benefit of Postoperative Radiotherapy in Non– Small-Cell Lung Cancer Damien Urban, MBBS, B Med Sc, Jair Bar, MD, PhD,

Use of Stereotactic Ablative Radiotherapy (SABR) in Non–Small Cell Lung Cancer Measuring More Than 5 cm Hilâl Tekatli, MD, Saar van ’t Hof, MD, Esther.

Prognostic Impact of Malignant Pleural Effusion at Presentation in Patients with Metastatic Non–Small-Cell Lung Cancer Daniel Morgensztern, MD, Saiama.

A Phase II Study of Concurrent Carboplatin and Paclitaxel and Thoracic Radiotherapy for Completely Resected Stage II and IIIA Non-small Cell Lung Cancer

Patient-Reported Quality of Life After Stereotactic Ablative Radiotherapy for Early-Stage Lung Cancer Frank J. Lagerwaard, MD, PhD, Neil K. Aaronson,

Pretreatment Anemia Portends Poor Survival and Nonlocal Disease Progression in Patients with Stage I Non–Small Cell Lung Cancer Treated with Stereotactic.

Samuel J. Wang, MD, PhD, C David Fuller, MD, Charles R. Thomas, MD

Thymoma—A Clinico-Pathological Long-Term Study with Emphasis on Histology and Adjuvant Radiotherapy Dose Thomas Harnath, MD, Alexander Marx, MD, Philipp.

Ziad Thotathil, MD, FRCR, Jeremy Long, FRACP

Maximum Standardized Uptake Value on FDG-PET Is a Strong Predictor of Overall and Disease-Free Survival for Non–Small-Cell Lung Cancer Patients after.

Central versus Peripheral Tumor Location: Influence on Survival, Local Control, and Toxicity Following Stereotactic Body Radiotherapy for Primary Non–Small-Cell.

Stereotactic body radiation therapy and 3-dimensional conformal radiotherapy for stage I non-small cell lung cancer: A pooled analysis of biological equivalent.

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab Tomoko Funazo,

Predictors of Death, Local Recurrence, and Distant Metastasis in Completely Resected Pathological Stage-I Non–Small-Cell Lung Cancer Jung-Jyh Hung, MD,

Safety and Efficacy of Stereotactic Body Radiotherapy for Stage I Non–Small-Cell Lung Cancer in Routine Clinical Practice: A Patterns-of-Care and Outcome.

Mediastinal Lymph Node Examination and Survival in Resected Early-Stage Non– Small-Cell Lung Cancer in the Surveillance, Epidemiology, and End Results.

Intratumoral Lymphatic Vessel Involvement is an Invasive Indicator of Completely Resected Pathologic Stage I Non-small Cell Lung Cancer Masahiko Harada,

Effects of Chemotherapy on Survival of Elderly Patients with Small-Cell Lung Cancer: Analysis of the SEER-Medicare Database Laura C. Caprario, MD, MS,

The Applicability of the Proposed IASLC Staging Revisions to Small Cell Lung Cancer (SCLC) with Comparison to the Current UICC 6th TNM Edition Sai-Hong.

Strategies to Improve Outcomes of Patients with EGFR-Mutant Non–Small Cell Lung Cancer: Review of the Literature Caicun Zhou, MD, PhD, Luan Di Yao, MD

Daniel Morgensztern, MD, Boone Goodgame, MD, Maria Q

Incidence and Risk Factors for Chest Wall Toxicity After Risk-Adapted Stereotactic Radiotherapy for Early-Stage Lung Cancer Eva M. Bongers, MD, Cornelis.

Patterns of Disease Recurrence after SABR for Early Stage Non–Small-Cell Lung Cancer: Optimizing Follow-Up Schedules for Salvage Therapy Naomi E. Verstegen,

Clinicopathological Characteristics of Screen-Detected Lung Cancers

Elizabeth Cathcart-Rake, MD, Ariel Lopez-Chavez, MD, MS

Neutrophil–Lymphocyte and Platelet–Lymphocyte Ratios as Prognostic Factors after Stereotactic Radiation Therapy for Early-Stage Non–Small-Cell Lung Cancer

EGFR delE709_T710insD: A Rare but Potentially EGFR Inhibitor Responsive Mutation in Non–Small-Cell Lung Cancer Allison Ackerman, MD, Michael A. Goldstein,

Trends in Stage Distribution for Patients with Non-small Cell Lung Cancer: A National Cancer Database Survey Daniel Morgensztern, MD, Shean Huey Ng,

Nicholas Trakul, MD, PhD, Jeremy P

Iris Metastasis from Small-Cell Lung Cancer

Role of Postoperative Radiotherapy in Nonlocalized Thymoma

The Prognostic Impact of Cigarette Smoking on Patients with Non-small Cell Lung Cancer Ryo Maeda, MD, Junji Yoshida, MD, PhD, Genichiro Ishii, MD, PhD,

Lymphovascular Invasion in Non–Small-Cell Lung Cancer: Implications for Staging and Adjuvant Therapy Kristin A Higgins, MD, Junzo P Chino, MD, Neal Ready,

Conditional Survival of Malignant Thymoma Using National Population-Based Surveillance, Epidemiology, and End Results (SEER) Registry (1973–2011) Ellen.

Maintenance Therapy and Advanced Non–Small-Cell Lung Cancer: A Skeptic's View Martin J. Edelman, MD, Thierry Le Chevalier, MD, Jean-Charles Soria, MD,

Ethnic Differences in the Management of Lung Cancer in New Zealand

Primary Small Cell Carcinoma of the Esophagus

Outcome of Multimodality Treatment for 188 Cases of Type B3 Thymoma

Stage I Non-small Cell Lung Cancer: Results for Surgery in a Patterns-of-Care Study in Sydney and for High-Dose Concurrent End-Phase Boost Accelerated.

Management of Mediastinal Relapse after Treatment with Stereotactic Body Radiotherapy or Accelerated Hypofractionated Radiotherapy for Stage I/II Non–Small-

Size matters: A comparison of T1 and T2 peripheral non–small-cell lung cancers treated with stereotactic body radiation therapy (SBRT) Neal E. Dunlap,

Liseth L. van den Berg, MD, Theo J. Klinkenberg, MD, Harry J. M

Surveillance Epidemiology and End Results Evaluation of the Role of Surgery for Stage I Small Cell Lung Cancer James B. Yu, MD, Roy H. Decker, MD, PhD,

Bortezomib Plus Gemcitabine/Carboplatin as First-Line Treatment of Advanced Non- small Cell Lung Cancer: A Phase II Southwest Oncology Group Study (S0339)

Stereotactic Body Radiotherapy for Central Lung Tumors

Effect of Tumor Size on Prognosis in Patients Treated with Radical Radiotherapy or Chemoradiotherapy for Non–Small Cell Lung Cancer: An Analysis of the.

A Review of First-Line Treatment for Small-cell Lung Cancer

Prognostic Significance of Tumor Size in Patients with Stage III Non–Small-Cell Lung Cancer: A Surveillance, Epidemiology, and End Results (SEER) Survey.

Reply to “Influence of Body Mass Index on Overall Survival Following Surgical Resection of Non–Small Cell Lung Cancer: Methodological Issues” Boris Sepesi,

Presentation transcript:

A Collaborative Analysis of Stereotactic Lung Radiotherapy Outcomes for Early-Stage Non–Small-Cell Lung Cancer Using Daily Online Cone-Beam Computed Tomography Image-Guided Radiotherapy Inga Siiner Grills, MD, Andrew J. Hope, MD, Matthias Guckenberger, MD, Larry L. Kestin, MD, Maria Werner-Wasik, MD, Di Yan, DSc, Jan-Jakob Sonke, PhD, Jean-Pierre Bissonnette, PhD, Juergen Wilbert, PhD, Ying Xiao, PhD, Jose Belderbos, MD, PhD Journal of Thoracic Oncology Volume 7, Issue 9, Pages 1382-1393 (September 2012) DOI: 10.1097/JTO.0b013e318260e00d Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 Distribution of prescription-dose BED10. BED10, biological equivalent doses; NKI, Netherlands Cancer Institute; TJU, Thomas Jefferson University Hospital; PMH, Princess Margaret Hospital. Journal of Thoracic Oncology 2012 7, 1382-1393DOI: (10.1097/JTO.0b013e318260e00d) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

Figure 2 Kaplan–Meier survival curves after lung stereotactic-body radiotherapy. (A) Local control, (B) regional control, (C) freedom from distant metastasis, (D) overall survival, and (E) cause-specific survival. Journal of Thoracic Oncology 2012 7, 1382-1393DOI: (10.1097/JTO.0b013e318260e00d) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

Figure 3 Local recurrence according to prescription biological equivalent doses. Journal of Thoracic Oncology 2012 7, 1382-1393DOI: (10.1097/JTO.0b013e318260e00d) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions